5-ALA与胶质瘤手术的FDA批准
美国FDA于2017年批准5-氨基乙酰丙酸(5-ALA;Gleolan®)作为术中光学成像剂,用于疑似高级别胶质瘤(HGG)患者。该批准较欧洲晚约十年,基于一项多中心III期随机试验,该试验证实5-ALA荧光引导手术较传统显微手术能实现更完整切除并改善患者结局。本文记录了FDA审批过程中的挑战,以强调脑肿瘤术中光学成像剂的新批准标准。
要点
- 5-ALA于2017年获FDA批准作为术中光学成像剂用于疑似HGG。
- 该批准基于多中心III期随机试验,显示5-ALA荧光引导手术较传统显微手术切除更完整、结局更好。
- FDA批准延迟主要源于5-ALA最初被概念化为治疗剂而非术中成像工具。
核心结论
- 5-ALA作为术中光学成像剂获FDA批准,标志着脑肿瘤术中光学成像剂审批新标准的建立。
研究设计与样本
- 本文为综述,回顾5-ALA获FDA批准的过程及相关多中心III期随机试验证据。
主要发现
- 5-ALA荧光引导手术作为手术辅助手段,在HGG患者中较传统显微手术能实现更完整切除并改善患者结局。
- FDA批准发生在欧洲批准及多中心III期随机试验证实上述优势约十年之后。
临床怎么用
- 作者认为5-ALA获FDA批准为脑肿瘤术中光学成像剂的审批建立了新标准。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The US Food and Drug Administration (FDA) approved 5-aminolevulinic acid (5-ALA; Gleolan®; photonamic GmbH and Co. KG) for use as an intraoperative optical imaging agent in patients with suspected high-grade gliomas (HGGs) in 2017. This was the first ever optical imaging agent approved as an adjunct for the visualization of malignant tissue during surgery for brain tumors. The approval occurred a decade after European approval and a multicenter, phase III randomized trial which confirmed that surgeons using 5-ALA fluorescence-guided surgery as a surgical adjunct could achieve more complete resections of tumors in HGG patients and better patient outcomes than with conventional microsurgery. Much of the delay in the US FDA approval of 5-ALA stemmed from its conceptualization as a therapeutic and not as an intraoperative imaging tool. We chronicle the challenges encountered during the US FDA approval process to highlight a new standard for approval of intraoperative optical imaging agents in brain tumors.
引用
- Hadjipanayis CG, Stummer W. 5-ALA and FDA approval for glioma surgery. J Neurooncol. 2019. PMID: 30644008. doi:10.1007/s11060-019-03098-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。